Help Privacy Policy Disclaimer
  Advanced SearchBrowse




Journal Article

Multi-specific antibodies for cancer immunotherapy


Jachimowicz,  R. D.
Jachimowicz – Mechanisms of DNA Repair, Max Planck Research Groups, Max Planck Institute for Biology of Ageing, Max Planck Society;

External Resource
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available

Jachimowicz, R. D., Borchmann, S., & Rothe, A. (2014). Multi-specific antibodies for cancer immunotherapy. BioDrugs, 28(4), 331-43. doi:10.1007/s40259-014-0091-4.

Cite as: https://hdl.handle.net/21.11116/0000-000B-83E8-B
Targeted treatment of cancer with monoclonal antibodies has added to the beneficial outcome of patients. In an attempt to improve anti-tumor activity of monoclonal antibodies, multi-specific antibodies have entered the research arena. To date, only a few multi-specific constructs have entered phase III clinical trials, in contrast to classical monoclonal antibodies, which are the standard first-line therapy in several tumor entities. In this review, we will assess selected multi-specific antibodies in pre-clinical and clinical development that may be new treatment options for cancer patients in the very near future. We will further evaluate therapy modalities including the timely distribution or the combination of various therapeutic approaches and assess the potential role of multi-specific antibodies in cancer treatment.